Patients may walk farther with SPINRAZA

CS2/CS12

Ambulatory patients (n=13) with later-onset (Type 3) spinal muscular atrophy (SMA) demonstrated a 92-meter increase from baseline of 253 meters at day 1150.1

Change in 6MWT distance from baseline after 1150 days1

Chart showing a change in 6 minute walk test distance from baseline after 1150 days
Chart showing a change in 6 minute walk test distance from baseline after 1150 days

92-meter increase1

6MWT=6-Minute Walk Test; SE=standard error.

All nonambulatory patients with Type 3 SMA reached the maximum Upper Limb Module score of 18 points by day 350 and maintained this score through day 1150.1

In a natural history cohort, it was shown that ambulation does not improve over time.2

SPINRAZA may help patients gain or regain the ability to walk.1

Among the nonambulatory patients who were unable to walk at baseline:

Walking icon

1 of 11 patients with Type 2 SMA gained the ability to walk for the first time

Walking icon

2 of 4 patients with Type 3 SMA regained the ability to walk that they had previously lost

Lauren
age 20

Later-onset (Type 3) SMA
treated with SPINRAZA

Lauren
age 20

Later-onset (Type 3) SMA
treated with SPINRAZA

Individual results may vary based on several factors, including severity of disease, initiation of treatment, and duration of therapy.